PTU - Polskie Towarzystwo Urologiczne
list of articles:

Zofran in nausea and vomiting prevention caused by Cytostatic drugs in patients with carcinoma of the testicle and urinary bladder
Article published in Urologia Polska 1993/46/4.


Jerzy Świerż, Bronisław Stawarz
Z Kliniki Urologii Centralnego Szpitala Klinicznego WAM w Warszawie
Kierownik Kliniki: Prof. dr hab. med. B. Stawarz


Effectiveness and toxicity evaluation is presented in ondansetron (zofran) treatment of
nausea and vomiting caused by Cytostatic drugs. In 38 patients (79%) the complete lack of
nausea and vomiting was obtained. Drug tolerance was good. Of essential side effects
constipation (38%) and headaches (31%) were found. Authors conclude that ondansetron is an
effective and safe drug against nausea and vomiting followed by cytostatics.


  1. 1.Brown G., Pees D., BrysonJ., Freeman A.: The effectiveness of single intravenous dose of ondansetron. Oncology 1992, 49, 273. —
  2. 2. Depiewe A., Lebean B., d\\\'Allens H.: A Comparison of ondansetron with alizapride plus methylprednisolone in the control of cisplatin induced emesis. Oncology, 1992, 42, 305. —
  3. 3. Finn A.: Toxicity and side effect of ondansetron. Semin. Oncol., 1992, 19, 53. —
  4. 4. Freeman A., Cunningham K., Tyers M.: Selectivity of 5HT3 receptor antagonists and antiemetic mechanisms of action. Anticancer Drugs, 1992, 3, 79. —
  5. 5. GandaraD., Harvey W., Monaghan G., Perez E., Stokes C: The delayed emeisi syndrome from cisplatin, phase III evaluation of ondansetron versus placebo. Semin. Oncol., 1992,19,67. —
  6. 6. Hainsworth J.\\\\ The use of ondansetron in patiens receiving multipleday cisplatin regimens. Semin. Oncol., 1992, 19, 48. —
  7. 7. Jurgens H., McQuade B.\\\\ Ondansetron as prophylaxis for chemotherapy and radiotherapy induced emesis in children. Oncology, 1992, 49, 279. —
  8. 8. KrisM., Tyson L., Cark R., Grralla R.: Oral ondansetron for the control of delayed emesis after cisplatin. Cancer, 1992, 70, 1012. —
  9. 9. Legha S., Hodges C, Ring S.: Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy. Cancer, 1992, 70, 2018. —
  10. 10. Morena J., Rosek R., Abad A., Barnadas A., Carles J.: Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin treated patients. Eur. J. Cancer, 1992, 28, 1344.
  11. 11.Seynaeve C, Mulder P., Lane A., Liessum P., Verweij J.: The 5TH3 receptor antagonist ondansetron reestablishes control in refractory emesis induced by non-cisplatin chemotherapy. Clin. Oncol. R. Coll. Radiol., 1991, 3, 199. —
  12. 12. Soukop M., McQuade B., Hunter E., Stewart A., Kaye S.: Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for brest cancer. Oncology, 1992, 49, 295. —
  13. 13. Tyres M., Freeman A.: Mechanism of antiemetic activity of 5HT3 receptor antagonists. Oncology, 1992, 49, 263.


dr med. Jerzy Swierż,
Klinika Urologii, Centralny Szpital Kliniczny WAM
00-909 Warszawa, ul. Szaserów 128